Background: Sleeve lobectomy for lung cancer in close proximity to or involving the carina is widely accepted.
INTRODUCTION
Sleeve lobectomy is removal of the part of the main stem bronchus in continuity with the adjacent lobe or bilobe followed by end-to-end bronchial anastomosis [1] . Since the first report by Price-Thomas [2] , sleeve lobectomy has been widely used to treat patients with lung cancer in close proximity to or involving the carina [3] [4] [5] [6] . Since sleeve lobectomy yielded survival results at least equal to those of pneumonectomy, as well as better functional results, it became an accepted procedure for patients with lung cancer who have anatomically suitable tumors, regardless of lung function [7] [8] [9] .
Functional lung parenchyma can be preserved, and the reimplanted lobes contribute to postoperative quality of life. If a second case of primary lung cancer develops, subsequent resection may be offered to selected patients [10, 11] . However, bronchial anastomotic complications and operative mortality rates show considerable variation across studies [12, 13] . We performed this study to determine the outcomes of our use of sleeve lobectomy for primary lung cancer. Findings from follow-up investigations were used to categorize recurrences as in the anastomosed area, regional, or distant.
MATERIALS AND METHODS

Between
The data were compared with the independent t-test.
Survival data were calculated according to the Kaplan-Meier method from the date of operation and included postoperative deaths. Any value of p less than 0.05 was considered statistically significant.
RESULTS
In the sleeve lobectomy group, there were 7 right upper lobectomies, 1 right lower lobectomy, 3 bilobectomies, 2 left upper lobectomies, and 6 left lower lobectomies. In the pneumonectomy group, there were 13 left pneumonectomies and 7 right pneumonectomies ( Table 1 disease. 10 (50%) had N0, 4 (20%) N1, and 6 (30%) N2 disease (Table 2 ).
In the sleeve lobectomy group, 1 patient had incomplete resection in which frozen sections of the bronchial margin were positive but pneumonectomy was contraindicated by the results of preoperative investigations. In the pneumonectomy group, all patients underwent complete resection. In the sleeve lobectomy group, postoperative radiation therapies were used in 2 patients and postoperative chemotherapies were used in 5 patients. 6 patients received both chemotherapy and radiation therapy after the operations. In the pneumonectomy group, postoperative radiation therapy was used in 1 patient and postoperative chemotherapy was used in 9 patients. 5 patients received both chemotherapy and radiation therapy after the operation (Table 2) (Table 3 ).
In the sleeve lobectomy group, the site of recurrence was the anastomosis site in 0, regional in 2, distant in 2, and locoregional and distant in 1. In the pneumonectomy group, the site of recurrence was regional in 2, distant in 5, and locoregional and distant in 2 ( Table 4 ). The 3-year survival rates were 46.7% in the sleeve lobectomy group and 54.5% in the pneumonectomy group (p=0.505) (Fig. 1) . The 3-year disease-free survival rates were 38% in the sleeve lobectomy − 416 − Fig. 1 . Three-year overall survival. Fig. 2 . Three-year recurrence-free survival.
group and 45.8% in the pneumonectomy group (p=0.200) (Fig. 2) .
DISCUSSION
Since the first report by Price-Thomas [2] , sleeve lobectomy has been generally used to treat patients with central bronchogenic cancer [3] [4] [5] [6] . However, bronchial anastomotic complications and operative mortality rates show significant variation across studies [12, 13] . Furthermore, the long-term results of sleeve resection in comparison with conventional lung cancer resections remain controversial, especially regarding nodal involvement and functional status [14] .
The major complications after performing sleeve resection were the narrowing of the bronchoplasty site and atelectasis, whereas the pneumonectomy group suffered primarily from postpneumonectomy empyema and respiratory failure.
A 1992 collective review of 1,915 bronchoplastic procedures performed during a 12-year period in patients with bronchogenic tumors found that sleeve lobectomy was followed by morbidity and mortality similar to pneumonectomy but allowed for better lung function preservation [3] . In recent studies, operative mortality has ranged from 0% to 5.2% [4, 6] , which is comparable to the range after standard lobectomy [15] and lower than after standard pneumonectomy [13, 16] . In our study, there was no operative mortality after sleeve lobectomy.
Specific procedure-related complications of bronchoplasty include impaired anastomotic healing and retention of bronchial secretions. The incidence of anastomotic dehiscence is estimated at approximately 3.5% [3] and reoperative management is rarely required. Bronchial ischemia is obvious following sleeve bronchoplasty. Reports of the overall incidence of stenosis range from 3 to 9% [3] . Retention of secretions may be associated with bronchial denervation, which has been shown to decrease mucociliary clearance and viscoelasticity of bronchial secretions [17] . The reported incidence varies from 4 to 12% [18] . We did not perform repetitive bronchoscopy for bronchial clearing, and there were no postoperative complications.
The risk of local recurrence is the main concern caused by the use of sleeve lobectomy to treat bronchogenic malignancy. Suture line recurrence may be related to lung preservation at the expense of adequate bronchial margins [3] .
Therefore, Paulson and colleagues [19] recommended that the bronchial resection margins be at least 1.5 cm away from the tumor. The incidence of local recurrence has ranged from 5% to 51% [7] . In a recent study comparing sleeve lobectomy with pneumonectomy for NSCLC, Okada and colleagues [13] found that the local recurrence rate was lower after bronchoplastic procedures. In our study, there was 1 (5.2%) locoregional with distant recurrence after sleeve lobectomy.
Van Schil [14] reported that nodal status was the most significant determinant of long-term survival after sleeve lobectomy, with significantly shorter survival in patients with N2
disease than in those with N1 or N0 disease. It has been
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− 417 − shown that N2 disease is highly predictive of distant recurrences [20] .
CONCLUSION
Sleeve lobectomy is accepted as appropriate for selected patients with resectable malignant tumors and presents an alternative to the otherwise unavoidable pneumonectomy, owing to low mortality and good preservation of pulmonary function.
